Eli Lilly Stock Calculator
Estimate your Eli Lilly ($LLY) stock returns over time
Eli Lilly Investment Calculator
Calculate potential returns on your Eli Lilly stock investment using historical performance data.
Investment Projection Results
Initial Investment:
—
Hold Period:
—
Expected Annual Return:
—
Future Value:
—
Total Return:
—
What This Means For You
Enter your investment details above to see personalized insights.
Investment Growth Over Time
Frequently Asked Questions
This calculator allows you to project returns on Eli Lilly stock over time. Input your initial investment, holding period, and return rate. Experiment with different values to see how compounding impacts your potential growth.
Eli Lilly has demonstrated varying returns across different time periods. The 5Y return of 428.28% provides the most comprehensive historical view. Our weighted average annual return of 249.45% gives more weight to longer-term performance. However, past performance doesn't guarantee future results, and returns can vary significantly year to year.
Several factors can influence Eli Lilly's stock performance:
- Company earnings and revenue growth
- Market conditions and economic trends
- Industry-specific developments
- Company announcements and news
- Overall market sentiment
The calculator provides two key metrics:
Future Value
The projected value of your investment at the end of your holding period
Total Return
The absolute dollar amount gained or lost, plus the percentage return on your investment
Remember that these are projections based on your inputs and historical data. Actual returns may differ significantly.
Explore More Stock Calculators
Historical Returns
1Y Return
-7.85%
2Y Return
77.33%
3Y Return
138.24%
4Y Return
291.27%
5Y Return
428.28%
YTD Return
-3.14%
Last Updated: 2025-06-04 14:21:18
Eli Lilly Information
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Business Classification
Sector
Healthcare
Industry
Drug Manufacturers - General
Location
Indianapolis, IN, United States
Company Size
47,000 employees
Website
Resources & Data Sources
Stock data powered by
Yahoo Finance API
Company logos provided by
Parqet Logo API
Market data and calculations are for informational purposes only and should not be considered as financial advice.
